Shares of biotech company Bioxcel Therapeutics soared 14% on Monday and hit an all-time intraday high of $71.50 after revealing bullish Phase 3 results for an agitation treatment in patients with schizophrenia. The company’s drug reduced agitation in patients with schizophrenia and bipolar disorder in two pivotal studies. Bioxcel is planning to ask for Food … Continue reading “Bioxcel Therapeutics Soars to Record High on Strong Schizophrenia Test Results”
